SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Arterial Vascular Engineering AVEI -- Ignore unavailable to you. Want to Upgrade?

To: Tim Bagwell who wrote (218)6/4/1998 1:42:00 AM
From: john  Read Replies (2) | Respond to of 410
 
Tim,

Thanks for the article. I feel a little better, but a $10 rise in the stock price would be nicer. I read a 5/13 report by Goldman, Sachs tonight. It still recommends AVEI with a $50/sh price target. "The June quarter appears to be very robust, with sales and earnings likely to far exceed Street expectations. Furthermore, early feedback from Europe suggests the gfx II will be a strong product, and at the margin will likely help AVEI gain further share." Maybe I should buy more?

John



To: Tim Bagwell who wrote (218)6/4/1998 6:33:00 AM
From: Jera Poole  Respond to of 410
 
Tim, Excellent. They truly seem to be intent on being more than a one-product flash. It's good to hear they have such a positive image with their neighbors. I like holding companies I can feel good about owning and make money also.
JP :-).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News